Vatelizumab

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameVatelizumab
Drug Alias NameUNII-A4R7G50030TMC-2003CHR-1103GBR-500SAR-339658
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionIntegrin alpha2/beta1 antagonistsImmunosuppressants
TargetsIntegrin alpha2/beta1
Therapy Area/IndicationsMultiple Sclerosis, Relapsing-RemittingColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSweden +[9] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlenmark Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofiGenzyme Corp
Active IndicationsN/A
Inactive IndicationsMultiple Sclerosis, Relapsing-RemittingColitis, Ulcerative

Other Information

ATC CodeN/A
Related LinksWikipedia